1. Home
  2. EXPO vs RARE Comparison

EXPO vs RARE Comparison

Compare EXPO & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exponent Inc.

EXPO

Exponent Inc.

HOLD

Current Price

$64.00

Market Cap

3.0B

ML Signal

HOLD

RARE

Ultragenyx Pharmaceutical Inc.

HOLD

Current Price

$29.95

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXPO
RARE
Founded
1967
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.7B
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
EXPO
RARE
Price
$64.00
$29.95
Analyst Decision
Buy
Strong Buy
Analyst Count
3
20
Target Price
$88.00
$59.10
AVG Volume (30 Days)
590.0K
3.0M
Earning Date
04-30-2026
05-05-2026
Dividend Yield
1.87%
N/A
EPS Growth
N/A
7.31
EPS
0.59
N/A
Revenue
$582,014,000.00
$673,000,000.00
Revenue This Year
$12.75
$13.12
Revenue Next Year
$8.50
$37.80
P/E Ratio
$105.15
N/A
Revenue Growth
4.21
20.13
52 Week Low
$51.91
$18.29
52 Week High
$81.95
$39.89

Technical Indicators

Market Signals
Indicator
EXPO
RARE
Relative Strength Index (RSI) 63.47 48.68
Support Level $53.40 $29.08
Resistance Level $69.49 $36.26
Average True Range (ATR) 1.97 1.79
MACD 0.40 -0.47
Stochastic Oscillator 92.35 7.21

Price Performance

Historical Comparison
EXPO
RARE

About EXPO Exponent Inc.

Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Share on Social Networks: